GLPBio

Immunology/Inflammation

Read More about this category

The immune and inflammation-related pathway including the Toll-like receptors pathway, the B cell receptor signaling pathway, the T cell receptor signaling pathway, etc.

Toll-like receptors (TLRs) play a central role in host cell recognition and responses to microbial pathogens. TLR4 initially recruits TIRAP and MyD88. MyD88 then recruits IRAKs, TRAF6, and the TAK1 complex, leading to early-stage activation of NF-κB and MAP kinases [1]. TLR4 is endocytosed and delivered to intracellular vesicles and forms a complex with TRAM and TRIF, which then recruits TRAF3 and the protein kinases TBK1 and IKKi. TBK1 and IKKi catalyze the phosphorylation of IRF3, leading to the expression of type I IFN [2].

BCR signaling is initiated through ligation of mIg under conditions that induce phosphorylation of the ITAMs in CD79, leading to the activation of Syk. Once Syk is activated, the BCR signal is transmitted via a series of proteins associated with the adaptor protein B-cell linker (Blnk, SLP-65). Blnk binds CD79a via non-ITAM tyrosines and is phosphorylated by Syk. Phospho-Blnk acts as a scaffold for the assembly of the other components, including Bruton’s tyrosine kinase (Btk), Vav 1, and phospholipase C-gamma 2 (PLCγ2) [3]. Following the assembly of the BCR-signalosome, GRB2 binds and activates the Ras-guanine exchange factor SOS, which in turn activates the small GTPase RAS. The original RAS signal is transmitted and amplified through the mitogen-activated protein kinase (MAPK) pathway, which including the serine/threonine-specific protein kinase RAF followed by MEK and extracellular signal related kinases ERK 1 and 2 [4]. After stimulation of BCR, CD19 is phosphorylated by Lyn. Phosphorylated CD19 activates PI3K by binding to the p85 subunit of PI3K and produce phosphatidylinositol-3,4,5-trisphosphate (PIP3) from PIP2, and PIP3 transmits signals downstream [5].

Central process of T cells responding to specific antigens is the binding of the T-cell receptor (TCR) to specific peptides bound to the major histocompatibility complex which expressed on antigen-presenting cells (APCs). Once TCR connected with its ligand, the ζ-chain–associated protein kinase 70 molecules (Zap-70) are recruited to the TCR-CD3 site and activated, resulting in an initiation of several signaling cascades. Once stimulation, Zap-70 forms complexes with several molecules including SLP-76; and a sequential protein kinase cascade is initiated, consisting of MAP kinase kinase kinase (MAP3K), MAP kinase kinase (MAPKK), and MAP kinase (MAPK) [6]. Two MAPK kinases, MKK4 and MKK7, have been reported to be the primary activators of JNK. MKK3, MKK4, and MKK6 are activators of P38 MAP kinase [7]. MAP kinase pathways are major pathways induced by TCR stimulation, and they play a key role in T-cell responses.

Phosphoinositide 3-kinase (PI3K) binds to the cytosolic domain of CD28, leading to conversion of PIP2 to PIP3, activation of PKB (Akt) and phosphoinositide-dependent kinase 1 (PDK1), and subsequent signaling transduction [8].

 

References

[1] Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors[J]. Nature immunology, 2010, 11(5): 373-384.

[2] Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity[J]. Immunity, 2011, 34(5): 637-650.

[3] Packard T A, Cambier J C. B lymphocyte antigen receptor signaling: initiation, amplification, and regulation[J]. F1000Prime Rep, 2013, 5(40.10): 12703.

[4] Zhong Y, Byrd J C, Dubovsky J A. The B-cell receptor pathway: a critical component of healthy and malignant immune biology[C]//Seminars in hematology. WB Saunders, 2014, 51(3): 206-218.

[5] Baba Y, Matsumoto M, Kurosaki T. Calcium signaling in B cells: regulation of cytosolic Ca 2+ increase and its sensor molecules, STIM1 and STIM2[J]. Molecular immunology, 2014, 62(2): 339-343.

[6] Adachi K, Davis M M. T-cell receptor ligation induces distinct signaling pathways in naive vs. antigen-experienced T cells[J]. Proceedings of the National Academy of Sciences, 2011, 108(4): 1549-1554.

[7] Rincón M, Flavell R A, Davis R A. The Jnk and P38 MAP kinase signaling pathways in T cell–mediated immune responses[J]. Free Radical Biology and Medicine, 2000, 28(9): 1328-1337.

[8] Bashour K T, Gondarenko A, Chen H, et al. CD28 and CD3 have complementary roles in T-cell traction forces[J]. Proceedings of the National Academy of Sciences, 2014, 111(6): 2241-2246.

Research Areas

Products Related to Immunology/Inflammation(4985)

  • GC72352 structure
    GC72352Fontolizumab
    CAS: 326859-36-3
    Purity: >97.00%

    Fontolizumab (HuZAF) es un anticuerpo monoclonal anti-IFN-gamma humanizado.

  • GC72354 structure
    GC72354Lampalizumab
    CAS: 1278466-20-8
    Purity: >99.00%

    Lampalizumab (RG 7417) es un anticuerpo monoclonal humanidirigido al Factor de complemento D en la vía alternativa del complemento.

  • GC72358 structure
    GC72358Perakizumab
    CAS: 89957-37-9
    Purity: >99.00%

    Perakizumab (RG4934) es un anticuerpo monoclonal IgG1κ humanicontra IL-17A (relacionado con interleucina).

  • GC72359 structure
    GC72359Quilizumab
    CAS: 1228538-47-3
    Purity: >96.00%

    Quilizumab (anticuerpo anti-humano NGcGM3 recombinante) es un anticuerpo monoclonal IgG1κ humani.

  • GC72363 structure
    GC72363Timolumab
    CAS: 1073538-99-4
    Purity: >98.00%

    Timolumab (BTT1023), un anticuerpo monoclonal recombintotalmente humano que se une específicamente al VAP-1.

  • GC72365 structure
    GC72365Visilizumab
    CAS: 219716-33-3
    Purity: >98.00%

    Visilizumab (anticuerpo anti-humano CD3E recombinante) es un anticuerpo monoclonal IgG2 humanide Unión al receptor anti-CD3.

  • GC72367 structure
    GC72367Vunakizumab
    CAS: 1792181-33-9
    Purity: 95.00%

    Vunakizumab (anticuerpo anti-humano IL17A recombinante) es un anticuerpo monoclonal recombinhumano IgGκ que se dirige a la IL-17A e inhisu interacción con el receptor IL-17.

  • GC72378 structure
    GC72378Neihulizumab
    CAS: 2158362-38-8
    Purity: >98.00%

    Neihulizumab (ALTB-168) es un anticuerpo agonista de punto de control inmunitario que se une al CD162 humano (PSGL-1), lo que lleva a una regulación negativa de las células t activadas.

  • GC72380 structure
    GC72380Vobarilizumab
    CAS: 1628814-88-9
    Purity: >97.00%

    Vobarilizumab (ALX-0061) es un anticuerpo monoclonal anti-IL-6R (mAb) (Kd: 0.19 pM).

  • GC72381 structure
    GC72381Sonelokimab
    CAS: 1414386-05-2
    Purity: >99.00%

    Sonelokimab (ALX 0761; M 1095) es un nanobodia trivalente compuesto de nanobodios monovalderivados del camélico específicos a la interleucina humana (IL)-17A, IL-17F, y albsérica humana VHHs.

  • GC72390 structure
    GC72390Anrukinzumab
    CAS: 910649-32-0
    Purity: >98.00%

    Anrukinzumab (IMA-638) es un anticuerpo monoclonal humanianti-il-13.

  • GC72391 structure
    GC72391Avdoralimab
    CAS: 2226393-85-5
    Purity: >95.00%

    Avdoralimab (IPH 5401) es un anticuerpo monoclonal IgGκ totalmente humano que se dirige al receptor 1 del complemento C5a (C5aR1) que impide su Unión al C5a.

  • GC72396 structure
    GC72396Cendakimab
    CAS: 2151032-62-9
    Purity: >99.00%

    Cendakimab (RPC4046; ABT 308; CC-93538) es un anticuerpo monoclonal selectivo, humani, recombinante contra la molécula de IL-13.

  • GC72397 structure
    GC72397Ziltivekimab
    CAS: 2226654-05-1
    Purity: >99.00%

    Ziltivekimab (COR-001) es un anticuerpo monoclonal humano anti-IL-6 eficaz para reducir la PCR sérica.

  • GC72415 structure
    GC72415Goflikicept
    CAS: 2416984-26-2
    Purity: >98.00%

    Goflikicept (RPH 104) es una proteína híbrique se une selectivamente e inactiva tanto la IL-1 − como la IL-1 − circul.

  • GC72418 structure
    GC72418Inolimomab
    CAS: 152981-31-2
    Purity: >98.00%

    Inolimomab es un anticuerpo monoclonal de cadena del receptor anti-interleucin2 (IL-2R).

  • GC72424 structure
    GC72424Lutikizumab
    CAS: 1791411-57-8
    Purity: >96.00%

    Lutikizumab (ABT-981) es una inmunoglobulina de doble dominio variable anti-IL-1α e IL-1β.

  • GC72426 structure
    GC72426Manfidokimab
    CAS: 2428381-56-8
    Purity: 95.00%

    Manfidokimab (AK120) es un anticuerpo monoclonal anti-interleucina 4 receptor alfa (IL-4R −) IgG4.

  • GC72428 structure
    GC72428Melrilimab
    CAS: 2222865-46-3
    Purity: >96.00%

    Melrilimab (GSK 3772847) es un anticuerpo monoclonal IgG2-kappa anti-IL1RL1/ST2/IL33R/DER4/FIT-1.

  • GC72429 structure
    GC72429Mirikizumab
    CAS: 1884201-71-1
    Purity: >98.00%

    Mirikizumab (LY3074828) es un anticuerpo monoclonal IgG4 humanidirigido a la subunidad P19 de la interleucina 23.

  • GC72433 structure
    GC72433Nemvaleukin alfa
    CAS: 2315268-27-8
    Purity: >99.00%

    Nemvaleukin alfa (ALKS 4230) es una proteína de fusión IL-2 que se une selectivamente a la afinintermedia IL-2R.

  • GC72456 structure
    GC72456Eblasakimab
    CAS: 2445460-16-0
    Purity: >99.00%

    Eblasakimab (ASLAN004; CSL-334) es un anticuerpo IgG4 humano que se dirige específicamente a IL13RA1 y se expresa principalmente por células CHO-K1.

  • GC72471 structure
    GC72471Remtolumab
    CAS: 1791410-27-9
    Purity: >99.00%

    Remtolumab (ABT-122) es una inmunoglobulina de dominio dual variable que neutrtanto el factor de necrosis tumoral (TNF -) como la IL-17A.

  • GC72473 structure
    GC72473Crovalimab
    CAS: 1917321-26-6
    Purity: >98.00%

    Crovalimab (SKY59; RO7112689) es un nuevo anticuerpo humanicontra C5 de una manera dependiente del pH con KDs de 15.2 nM y 16.8 μM a pH 7.4 y 5.8, respectivamente.